{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 33 of 51', 'Study ID RCB: 2020-A00652-37', '9.8.2', 'Baseline characteristics', 'Baseline and demographic characteristics will be described on the analysis population and will', 'be summarized using appropriate summary statistics such as mean, standard deviation,', 'median, minimum and maximum for continuous variables, and frequency counts and', 'percentages for categorical variables.', '9.8.3', 'Sensitivity/sensibility analysis', 'Analysis of the primary endpoint', 'The primary endpoint will be the evaluation at week 12/16 of the sensitivity and the specificity,', 'compared to the DLQI as a standard, of the PSO-TARGET QoL component grid to assess the', 'level of satisfaction of patient achieving the therapeutic goal, identified by himself.', 'The therapeutic objective will be considered as achieved if the patient gives the responses', '\"Satisfied\" or \"Very Satisfied\" on the Likert scale. The response will then be compared to the', 'DLQI score at 12/16 weeks.', 'It will be described on the efficacy population.', 'A contingency table will be constructed as follows:', 'PSO-TARGET \\\\ DLQI', '0-1', '2-5', '6-10', '11-20', '21-30', 'Very satisfied', 'TP', 'FP', 'FP', 'FP', 'FP', 'Satisfied', 'TP', 'FP', 'FP', 'FP', 'FP', 'Unsatisfied', 'FN', 'TN', 'TN', 'TN', 'TN', 'Very unsatisfied', 'FN', 'TN', 'TN', 'TN', 'TN', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 34 of 51', 'Study ID RCB: 2020-A00652-37', 'This table can be summarized as :', 'PSO-TARGET \\\\ DLQI', '0-1', ' 2', 'Very satisfied ou', 'TP', 'FP', 'Satisfied', 'Unsatisfied', 'FN', 'TN', 'ou Very unsatisfied', 'TP: True positive', 'FP: False Positive', 'FN: False Negative', 'TN: True Negative', 'The validity of the QoL component grid will then be assessed by calculating the following', 'parameters:', 'Sensitivity: defined as the probability to have patients who have reached their therapeutic', 'target (who have responded \" satisfied \" or \" very satisfied \" on the Likert scale, globally and', 'in each major domains) among patients with a DLQI score between 0 and 1.', 'In other terms the sensitivity is defined as the concordance of the QoL component grid and', 'the DLQI for the patients with optimal quality of life.', 'The sensitivity is calculated by:', 'TP', '= TP + FN', 'Specificity: defined as the probability to have patients who have not reached their therapeutic', 'target (who have responded \" unsatisfied \" or \" very unsatisfied \" on the Likert scale, globally', 'and in each major domains) among patients with a DLQI score >2.', 'In other terms the specificity is defined as the concordance of the QoL component grid and', 'the DLQI for the patients with suboptimal quality of life.', 'The specificity is calculated by:', 'TN', '= +', 'The QoL component grid will be validated if these two parameters reach the threshold of 85%.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 35 of 51', 'Study ID RCB: 2020-A00652-37', 'Objective', 'Statistical analysis', 'Exposure measure', 'Outcome measure', 'Covariables', '1', 'Contingency table;', 'N/A', 'Concordance level', 'N/A', 'Sensitivity /', 'between PSO-', 'Specificity', 'TARGET Component', 'grid and DLQI at', '12/16 weeks', 'Analysis of the secondary performance endpoints', 'Analyses of secondary endpoints will be performed on the efficacy population.', 'No replacement of missing data will be performed.', 'The same analysis as the primary performance analysis will be performed at 52 weeks.', '9.8.4 Efficacy analysis', 'Secondary objective/endpoint : achievement of target objective at 12 weeks, per', 'component', 'Evaluation at week 12/16 of the level of achievement of the main treatment goal identified by', 'the patient in the table at baseline. This evaluation will be performed using a Likert scale in 4', 'points (\"very satisfied\", \"satisfied\", \"unsatisfied\", \"very unsatisfied\").', 'The achievement of the main treatment goal will be defined as a \"satisfied or very satisfied\"', 'response.', 'It will be described on the efficacy population.', '-', 'The proportion of patients with achievement of the main treatment goal will be described', 'and the confidence interval at 95% will be provided.', '-', 'The primary analysis will be performed with considering missing data as non responder,', 'and a sensitivity analysis will be performed on patients without missing data (observed', 'case).', '-', 'Search for predictive factors of efficacy.', 'The predictive factors of the achievement of the main treatment goal on completed patients', 'will be searched among baseline characteristics using binary logistic regressions models.', 'Univariate analyses will be used to select (p-value 0.20) the explanatory variables to include', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 36 of 51', 'Study ID RCB: 2020-A00652-37', 'in the multivariate model. The results of univariate and multivariate analyses will be', 'interpreted in terms of odds-ratios with their 95% confidence intervals', 'In case of correlated variables, only the more significant in univariate will be include in the', 'multivariate model.', 'Variables with a rate of missing data 20%, or those with empty categories or with very small', 'number will not be considered eligible for this research of predictive factors.', 'As part of one of the secondary objectives, the analyses performed for the efficacy endpoint', 'are summarized in the table below :', 'Objective', 'Statistical analysis', 'Exposure measure', 'Outcome measure', 'Covariables', '2.a', 'Proportions', 'N/A', 'Achievement of the', 'N/A', 'main goal (yes/no) at', '12/16 weeks', '2.b', 'Proportions -', 'N/A', 'Achievement of the', 'N/A', 'sensitivity analysis', 'main goal (yes/no) at', '12/16 weeks', '2.c', 'Binary logistic', 'N/A', 'Achievement of the', 'Relevant', 'regression models,', 'main goal (yes/no) at', 'confounders (eg :', '12/16 weeks', 'demographic data,', 'medical history,', 'previous treatment...)', '2.d', 'Proportions', 'N/A', 'Achievement of the', 'N/A', 'main goal (yes/no) at', '12/16 weeks for each', 'component', '9.8.5', 'Other secondary analyses', '-', 'Description and evolution of PASI', 'The PASI score will be described at baseline, W12/16 and W52.', 'The change in the PASI score between baseline and W12/16 then between baseline and W52', 'will be described by summary descriptive statistics, including 95% confidence interval of the', 'mean.', '-', 'Evolution of DLQI', 'The change in the DLQI score between baseline and W12/16 then between baseline and W52', 'will be described by summary descriptive statistics, including 95% confidence interval of the', 'mean.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']", "completion": ""}